v3.20.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Operating expenses:    
Research and development $ 9,738,819 $ 4,368,784
General and administrative 24,810,712 12,881,027
Depreciation and amortization 54,349 12,403
Total operating expenses 34,603,880 17,262,214
Loss from operations (34,603,880) (17,262,214)
Other income (expense):    
Interest income, net 132,751 10,897
Gain on disposal of assets 452 0
Loss before income taxes (34,470,677) (17,251,317)
Income taxes (benefit) 0 0
Net loss (34,470,677) (17,251,317)
Preferred stock dividend (25,163) (884,736)
Net loss attributable to common stockholders (34,495,840) (18,136,053)
Non-controlling interest 415,849 0
NET LOSS ATTRIBUTABLE TO BIOSIG TECHNOLOGIES, INC. $ (34,079,991) $ (18,136,053)
Net loss per common share, basic and diluted (in Dollars per share) $ (1.65) $ (1.25)
Weighted average number of common shares outstanding, basic and diluted (in Shares) 20,694,662 14,504,360

Source